Status:
COMPLETED
An Open-label Extension Study of Canakinumab in Patients With Systemic Juvenile Idiopathic Arthritis and Active Systemic Manifestations Manifestations and Response Characterization Study in Canakinumab Treatment-naïve Patients With Active SJIA With and Without Fever.
Lead Sponsor:
Novartis Pharmaceuticals
Collaborating Sponsors:
Pediatric Rheumatology International Trials Organization
Conditions:
Systemic Juvenile Idiopathic Arthritis
Eligibility:
All Genders
2-19 years
Phase:
PHASE3
Brief Summary
This open-label extension study will permit patients with Systemic Juvenile Idiopathic Arthritis (SJIA) who previously were responsive to treatment with canakinumab and canakinumab treatment-naïve pat...
Eligibility Criteria
Inclusion
- Inclusion criteria:
- Patients from study CACZ885G2305 or CACZ885G2301 who achieved an adapted ACR pediatric 30 response 15 days after their initial dose of canakinumab but clinically deteriorated afterwards or a minimum ACR Pediatric 30 response was not maintained after Day 15 and intervention is deemed necessary by the investigator, or Patients in study CACZ885G2301 who are not eligible to enter Part II (withdrawal part) because they were not able to meet the corticosteroid entry criteria , or Responder patients in Part I or Part II who had not flared when CACZ885G2301 was stopped, or CACZ885G2301 patients who were responders in Part I but experienced a flare in Part II.
- Treatment-naïve patients need to meet the following criteria:
- Confirmed diagnosis of systemic juvenile idiopathic arthritis as per ILAR definition that must have occurred at least 2 months prior to enrollment with onset of disease \< 16 years of age
- Male and female patients aged ≥ 2 to \< 20 years of age
- Active disease at the time of enrollment defined as having 2 or more of the following:
- Documented spiking, intermittent fever (body temperature \> 38°C) for at least 1 day during the screening period and within 1 week before first canakinumab dose
- At least 2 joints with active arthritis
- AND C-reactive protein (CRP) \> 30 mg/L (normal range \< 10 mg/L) Rash Serositis Lymphadenopathy Hepatosplenomegaly
- Naïve to canakinumab
- Other protocol-defined inclusion criteria may apply
- Exclusion criteria:
- History of allergy or hypersensitivity to study drug
- With active or recurrent bacterial, fungal or viral infections at time of enrollment
- Other protocol inclusion/exclusion criteria may apply
Exclusion
Key Trial Info
Start Date :
September 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2014
Estimated Enrollment :
270 Patients enrolled
Trial Details
Trial ID
NCT00891046
Start Date
September 1 2009
End Date
December 1 2014
Last Update
March 26 2019
Active Locations (73)
Enter a location and click search to find clinical trials sorted by distance.
1
Novartis Investigative Site
Los Angeles, California, United States, 90027
2
Novartis Investigative Site
Louisville, Kentucky, United States, 40202
3
Novartis Investigative Site
Boston, Massachusetts, United States, 02111
4
Novartis Investigative Site
Cincinnati, Ohio, United States, 45229